Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.3% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price dropped 7.3% during trading on Monday . The company traded as low as $23.60 and last traded at $23.7890. Approximately 27,765 shares were traded during trading, a decline of 93% from the average daily volume of 413,495 shares. The stock had previously closed at $25.67.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Trading Up 15.5%

The stock’s fifty day moving average is $26.86 and its two-hundred day moving average is $21.58.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Regencell Bioscience by 5,637.5% in the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after purchasing an additional 384,250 shares during the period. Squarepoint Ops LLC bought a new position in Regencell Bioscience during the second quarter worth about $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience during the second quarter worth approximately $768,000. XTX Topco Ltd acquired a new position in Regencell Bioscience during the third quarter worth approximately $598,000. Finally, Vident Advisory LLC raised its stake in Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares during the period. 0.13% of the stock is currently owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.